



AcompliaReport

HOME

Your **INDEPENDENT** source of news about the diet drug Acomplia (rimonabant)
Neither affiliated with nor endorsed by Sanofi-

[What Is Acomplia / Rimonabant / Zimulti?](#)

[Clinical Trials](#)

[Side-Effects](#)

[What Doctors Say?](#)

[Should I Consider Taking Acomplia?](#)

[Where Can I Buy Acomplia?](#)

[Other Drugs](#)

[Ads by Goooooogle](#)

Acomplia News from July 2006 -- News about Rimonabant

Study: Diet Drug Acomplia May Have Role in Fighting Breast Cancer

Stage 4 Breast Cancer

Femara information for healthcare professionals.
www.femarainfo.com

On top of the many cardiometabolic benefits claimed for diet pill Acomplia (rimonabant) comes another intriguing finding by Italian researchers: the possibility that Acomplia may slow the spread of one of the more dangerous forms of breast cancer.

The Cancer Project

Nutrition and Diet Resource for Cancer Prevention and Survival
www.cancerproject.org

In a paper that has been accepted for publication in a future issue of Molecular Pharmacology, lead researcher Maurizio Bifulco of the Università degli Studi di Salerno reports that the CB1 cannabinoid receptor Acomplia "inhibited human breast cancer cell proliferation" in both rodent and test tube studies.

Perhaps most intriguing was the discovery that rimonabant was most effective in inhibiting the growth of a highly aggressive metastatic breast cancer cell line called MBA-MB-231.

Living with Breast Cancer

A moving & important book. Full of valuable information. a great read!
www.cmspress.com

The metastatic spread of breast tumors accounts for the majority of cancer-related deaths, and these tumor colonies typically fail to respond to conventional therapies.

In their test tube studies, the researchers said they checked the effect of different doses of rimonabant on tumor cell proliferation against highly invasive metastatic, estrogen receptor negative MDA-MB-231 breast cancer cells as well as against less invasive estrogen receptor positive T47D and MCF-7 cells.

Breast Cancer Treatment

The Latest Online Source You Will Find It Here!
ebreastcancertreatment.n

"The growth of highly invasive metastatic MDA-MB-231 cells was inhibited more efficaciously than that of less invasive T47D and MCF-7 cells," the researchers reported.

In their tests using mice, the researchers injected the mice with MDA-MB-231 cancer cells and when tumors were clearly detectable 15 days later, gave the mice either rimonabant or a placebo.

[Advertise on this site](#)

"Tumor growth was monitored and the data revealed that exposure to rimonabant led to a significant decrease in tumor mass compared to control-treated mice," the researchers said. The mice treated with rimonabant "exhibited no outward signs of toxic or hypolocomotor effects," the researchers added.

The findings of the Italian researchers are one more building block in the growing understanding of the endocannabinoid system, which they describe as "an almost ubiquitous signalling system involved in the control of cell fate."

One key observation is that the CB1 receptor -- which rimonabant blocks -- is found to a greater extent in some lines of breast cancer than in others, and that the effectiveness of rimonabant against breast cancer tumors is to some extent dependent on the expression levels of CB1 receptor.

"The present findings provide unequivocal evidence for the role of the CB1 receptor and its antagonist/inverse-agonist rimonabant in breast tumor cell proliferation," the researchers concluded.

For those with a scientific background who would like to read the report by the Italian researchers in its entirety, it can be found at <http://molpharm.aspetjournals.org/cgi/reprint/mol.106.025601v1>

The Italian study was partially funded by the developer of Acomplia, Sanofi-Aventis.

Breast Cancer Strategies

11 steps to winning the battle against breast cancer.
www.CancerFightingStrategies.com

Breast Cancer

Find info on Breast Cancer. Know your options.
www.eBreastCancer.info

Living with Breast Ca

A moving & important book of information. a great read!
www.cmspress.com

Ads by Goooooogle

Consumer Ad Alert!



We subscribe to the HONcode principles of the HON Foundation.

Privacy Policy | Terms and Disclaimers | About the Acomplia Report

This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Synthelabo Inc., which plans to market it under the trademarked name Acomplia. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.